Rege Nephro Acquires Tamibarotene from Syros Pharmaceuticals to Enhance Kidney Disease Treatments
- Rege Nephro acquired Tamibarotene from Syros Pharmaceuticals to enhance kidney disease treatment capabilities.
- Tamibarotene is in a Phase 2 trial for ADPKD, with plans to expand to the U.S. market.
- Syros previously conducted Phase 3 trials for Tamibarotene, indicating its versatility across different therapeutic areas.
Rege Nephro Expands Clinical Portfolio with Acquisition of Tamibarotene from Syros Pharmaceuticals
In a significant development within the biotechnology sector, Rege Nephro Co., Ltd., based in Kyoto, Japan, successfully acquires clinical and non-clinical assets related to Tamibarotene from Syros Pharmaceuticals, Inc. of Boston, MA, finalizing the transaction on February 26, 2025. This acquisition marks a strategic move for Rege Nephro, enhancing its capabilities in developing innovative treatments for kidney diseases. Tamibarotene (RN-014), a retinoic acid receptor agonist, is currently being evaluated in a Phase 2 clinical trial for autosomal dominant polycystic kidney disease (ADPKD) in Japan, with plans to broaden the trial's scope to the United States contingent on successful preliminary results regarding its efficacy and safety.
As part of the acquisition, Rege Nephro secures a wealth of resources including comprehensive clinical data, human safety studies necessary for New Drug Application (NDA) submissions, and contracts with a contract manufacturing organization (CMO). These assets are expected to streamline the company's operational processes, particularly as it seeks to leverage Tamibarotene’s potential in the U.S. market. Previously, Syros Pharmaceuticals conducted a Phase 3 clinical trial for Tamibarotene, targeting myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), showcasing the drug's versatility and potential applicability across different therapeutic areas.
Rege Nephro, founded in 2019, specializes in developing therapeutics for kidney, liver, and pancreatic diseases, drawing on advanced technologies from Kyoto University’s Center for iPS Cell Research and Application (CiRA). The Phase 2 clinical trial for RN-014 commenced in December 2023, and preliminary findings indicate no significant safety concerns along with early signs of efficacy, reinforcing the drug's potential as a treatment option for ADPKD. The successful completion of this acquisition not only strengthens Rege Nephro’s clinical pipeline but also positions the company to better navigate the complex landscape of drug development in the field of nephrology.
In tandem with this acquisition, Rege Nephro's focus on innovative cell therapies and therapeutics aligns with its mission to address unmet medical needs in organ diseases. This strategic acquisition signifies a robust commitment to enhancing patient outcomes through advanced research and development, setting the stage for potential breakthroughs in kidney disease treatment. As the company continues to progress with its clinical trials, the biotechnology community closely monitors its developments, anticipating the impact of RN-014 on patient care in the United States and beyond.